explore -WSS

explore

author：hotspot 2025-09-28 23:30:44 - browse：6

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Novartis develops a rapidly manufactured CAR

leisure time

WSS

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Winning ticket for $1 billion Powerball jackpot sold in California

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Stanford president faces new allegations over 1999 paper

7 more heat

entertainment

explore

knowledge

Psychedelics group wrestles with new pharma identity

Indian pharmaceutical industry in denial over drug

Moonlake's readout produced a cash windfall. Risks remain

Tocagen's brain cancer gene therapy trial continues. Investors worry

Cancer drug shortages should be causing more outrage

I learned firsthand about improving diversity in clinical trials

Walensky prepares to leave CDC — and Congress — behind

Stanford president's case begs question: Who takes blame?

Dobbs anniversary: the lost opportunity of abortion as health care

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

leisure time

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

FAMU bans football players from facility after release of rap video shot in team's locker room

Novartis develops a rapidly manufactured CAR

I learned firsthand about improving diversity in clinical trials

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

FDA approves first blood sugar monitor without finger pricks

leisure time

Wikipedia

focus

entertainment